Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct 13;1(3):218-220.
doi: 10.1158/2643-3230.BCD-20-0151. eCollection 2020 Nov.

Don't Compromise Myeloma Care Due to COVID-19 Pandemic!

Nikhil C Munshi  1   2 , Kenneth C Anderson  1
Affiliations
Comment

Don't Compromise Myeloma Care Due to COVID-19 Pandemic!

Nikhil C Munshi et al. Blood Cancer Discov. .

Abstract

Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome. See related video: https://vimeo.com/486246183/559a80cfae See related article by Hultcrantz et al., p. 234.

PubMed Disclaimer

Conflict of interest statement

N.C. Munshi reports personal fees from Bristol-Myers Squibb (consultant), Janssen (consultant), Amgen (consultant), Takeda (consultant), Abbvie (consultant), and other from OncoPep (scientific founder) outside the submitted work. K.C. Anderson is a consultant/advisor for Bristol-Myers Squibb, Janssen, Amgen, Takeda, Sanofi, Gilead, and Precision Biosciences and Scientific Founder of OncoPep and C4 Therapeutics. One of the Editors-in-Chief is an author on this article. In keeping with the AACR's editorial policy, this submission was managed by a member of Blood Cancer Discovery's editorial team; independently, AACR's Editorial Director rendered the final decision concerning acceptability.

Comment on

References

    1. Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov 2020;1:234–43. - PMC - PubMed
    1. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov 2020. Jul 31 [Epub ahead of print]. - PMC - PubMed
    1. Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol 2020;190:e83–e6. - PMC - PubMed
    1. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in MM: International Myeloma Society COVID-19 dataset. medRxiv 2020.08.24.20177576 [Preprint]. 2020. Aug 31. Available from: 10.1101/2020.08.24.20177576. - DOI - PMC - PubMed
    1. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372–74. - PMC - PubMed